Cochrane · systematic review · CD006127
Blood pressure control for diabetic retinopathy
Do, DV, Han, G, Abariga, SA, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 71.4%Very low 1 · 14.3%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyBlood pressure intervention/intensive blood pressure intervention compared with placebo/standard blood pressure intervention for diabetic retinopathy
Population: type 1 or type 2 diabetics
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of retinopathy by 5 years Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention | no estimate extracted | 1 participants | Ungraded |
Progression of retinopathy by 5 years Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention | no estimate extracted | 1 participants | Ungraded |
Combined incidence and progression of diabetic retinopathy by 5 years Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention | no estimate extracted | 1 participants | Ungraded |
Incidence of PDR/CSME/VH by 5 years Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention | no estimate extracted | 1 participants | Ungraded |
Visual acuity (loss of 3 lines or more) by 5 years Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention | RR 1.15 [0.63, 2.08] | 2 studies · 2326 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events—all‐cause mortality Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention | no estimate extracted | 1 participants | Ungraded |
Adverse events—hypotension Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention | RR 2.04 [1.63, 2.55] | 2 studies · 3323 participants | Low Downgraded: risk of bias, imprecision |
Comparison
Population: type 1 or type 2 diabetics
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of retinopathy at 4 to 5 years | RR 0.8 [0.71, 0.92] | 6 studies · 3053 participants | Moderate Downgraded: risk of bias |
Progression of retinopathy at 4 to 5 years | RR 0.88 [0.73, 1.05] | 4 studies · 4105 participants | Moderate Downgraded: risk of bias |
Combined incidence and progression of diabetic retinopathy, 4 to 5 years | RR 0.78 [0.63, 0.97] | 5 studies · 2587 participants | Low Downgraded: risk of bias, inconsistency |
Incidence of PDR/CSME at 4 to 5 years | RR 0.95 [0.83, 1.08] | 6 studies · 6089 participants | Moderate Downgraded: risk of bias |
Visual acuity at 4 to 5 years | RR 1.06 [0.85, 1.33] | 2 studies · 2326 participants | Moderate Downgraded: inconsistency |
Adverse events ‐ All‐cause mortality | RR 0.86 [0.64, 1.14] | 7 studies · 6709 participants | Moderate Downgraded: risk of bias |
Adverse events ‐ Hypotension | RR 2.08 [1.68, 2.57] | 3 studies · 3477 participants | Moderate Downgraded: risk of bias |